First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial

Luis G Paz-Ares, Tudor–Eliade Ciuleanu, Manuel Cobo et al. · The Lancet Oncology · 2021

Cited by 1,357 works. doi:10.1016/s1470-2045(20)30641-0

Authors

References